DLDan Li

Dan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan Li has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Dan Liu

    Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Mei Li

    Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Panwen Tian

    Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West China Hospital, chengdu, China

    1 shared publication
  • Weimin Li

    Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Xia Yuan

    Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu, 610041, People’s Republic of China

    1 shared publication
  • Yue Cheng

    Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Initial Experience with Cryoablation for Oligoprogressive Metastatic NSCLC on First-Line Immunotherapy

    by Dan Li, Yue Cheng, Dan Liu, Panwen Tian, Weimin Li

    Background: This prospective study evaluated the initial outcomes of local cryoablation for patients with oligoprogressive metastatic non-small cell lung cancer (NSCLC) who were maintained on first-line immunotherapy. Methods: The study included patients diagnosed with oligoprogressive metastatic NSCLC while undergoing first-line immunotherapy. Clinical outcomes, treatment efficacy, and procedural complications of cryoablation were reviewed. Results: Ten patients with oligoprogressive metastatic NSCLC on first-line immunotherapy underwent percutaneous c Panwen ryoablation at West China Hospital between September 2024 and November 2025. All patients continued their original immunotherapy regimen following ablation. Technical success was defined as ≥90% coverage of the target lesion by the ablation zone. Postprocedurally, one patient experienced mild hemoptysis, and another developed a pneumothorax requiring drainage. No other significant adverse events occurred. The disease control rate at 3 months was 70% (7/10), and progression-free survival ranged from 1.7 to 6 months. Conclusions: In this initial case series, local cryoablation appears to be an effective and safe therapeutic strategy for managing oligoprogressive disease in metastatic NSCLC patients continuing first-line immunotherapy.

  • Open Access

    Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings

    by Xia Yuan, Yuliang Feng, Dan Li, Mei Li

    Background: Visual impairment occurred as an infrequent form of chemotherapeutic toxicity and was often underestimated despite of several reports. We described a case of acute unilateral visual impairment after one cycle of intravenous chemotherapy of a normal dose, aiming at raising attention to chemotherapy-induced ocular toxicity. Case presentation: The patient developed a progressive vision loss in the right eye during the chemotherapy. After one cycle of intravenous chemotherapy, her visual acuity decreased by 0.6 in the right eye (VOD = 0.4) compared to the previous value of 1.0 (VOD = 1.0). No evidence of ocular infiltration was observed from the cerebral magnetic resonance imaging (MRI). During her follow-up period, we documented the ophthalmologic examinations including visual acuity, visual field (VF), visual evoked potential (VEP), electroretinogram (ERG), fundus photograph (FP), fundus fluorescein angiography (FFA) and optical coherence tomography (OCT). Ophthalmoscope examination and fundus photograph showed optic disc edema, fuzzy boundary and linear hemorrhages in her right eye. Fundus fluorescein angiography (FFA) revealed capillary underdevelopment at the nasal and superior temporal area of the optic disc in the early phase and capillary fluorescein leakage in the late phase. The result of VEP test suggested the impaired function of the optic nerve. Thus, a diagnosis of nonarteritic anterior ischemic optic neuropathy (NAION) was made by the ophthalmologist according to these results. The patient was prescribed prednisone combined with neuroprotective drugs, which did not work. After the cessation of chemotherapy, her impaired vision gradually recovered. Conclusions: This is the first reported case of acute visual impairment in a patient who underwent chemotherapy of a normal dose. It is indicated that while receiving benefits from chemotherapy, cancer patients simultaneously suffer from the risk of vision loss.